



Webinar series:

T-cell immune monitoring to improve transplant outcomes



Can T-cell testing help you tailor care for your transplant patients?

Opportunistic infections have an increased incidence in the first-year post-transplant, when immunosuppression tends to be at its highest.

- What if you were able to assess the level of T-cell immune response (CMI) during immune suppression and stratify the risk of infections and graft rejection in transplant recipients to guide your therapeutic approach?
- What if you were able to assess the ability of a transplant patient to gain restored immunity against infectious diseases?

Join four experts to learn about T-cell immunity in transplant medicine and infectious diseases.

You'll learn about:

- Potential roles of T-cell immune response monitoring in infection prevention
- How QuantiFERON® Interferon-Gamma Release Assays (IGRAs) can be used in this context

September 15
5 PM CET

A review of the potential roles of T-cell immune response monitoring in the management of transplant patients

Pr. Paul Moss (University of Birmingham, UK)

October 13
5 PM CET

Prevention of TB reactivation in transplant patients: a clinical case of TB in transplant

Pr. Pierre Tattevin (Rennes University hospital, FR)

November 22
5 PM CET

Managing the risk of CMV infection in transplant: guidelines & clinical value of CMV IGRA

Dr. Camille Kotton (Massachusetts General Hospital, USA)

December 6
12 PM CET

Case study: Reducing infection risks in transplant recipients, roles of generic & specific T-cell response monitoring with IGRA

Dr. Tess McClure (Austin Health, AU)

This webinar series is free to attend and offers CPD accreditation.



Register now at www.qiagen.com/transplant-webinars



Missed the live event?


Don't worry – you can also use this link to watch the on-demand recording.

Sample to Insight

About the speakers

Professor Paul Moss

Professor of Hematology and Deputy Head of the College of Medical and Dental Sciences at the University of Birmingham



Paul Moss is a leading international figure in translational human immunology, studying in particular both the pathogenic and therapeutic potential of T cell responses. Professor Moss's research program is based around the immunology of cancer, transplantation and viral infection. His team has an internationally competitive position in cytomegalovirus infection, bone marrow transplantation and cancer immunology. He is a Clinical Hematologist and has run several innovative clinical trials. Professor Moss is Principal Investigator of the UK Coronavirus Immunology Consortium (UK-CIC), a £6.5 million initiative to bringing together immunologists from 19 UK research centers to answer key questions on how the immune system interacts with SARS-CoV-2 to help us fight COVID-19 and develop better diagnostics, treatments and vaccines.

Professor Pierre Tattevin

Medical doctor and professor in Infectious diseases at Rennes University hospital in France. President of the French Society of Infectious pathologies (SPIILF) since 2018



Pierre Tattevin, MD, PhD, is a 53-year-old physician specialized in infectious diseases. He was trained in Paris (fellowship), Rennes (PhD), and San Francisco (post-doc). He is the head of the department of Infectious Diseases in the Rennes University Hospital (France). In addition, he is responsible of the ID research field in his institution. He authored or co-authored >500 papers indexed in Pubmed, mostly as a first or last author. His H-index is 43.

Dr. Camille Kotton


Medical doctor, Infectious Disease Specialist, Clinical Director of the Transplant and Immunocompromised Host Infectious Diseases in the Infectious Diseases Division at the Massachusetts General Hospital



Camille Kotton spends the majority of her time seeing inpatients and outpatients, before and after solid organ and bone marrow transplant, as well as other immunocompromised hosts. Her interests include vaccination, travel medicine for transplant recipients, and reducing the infectious risks of immunocompromising medications. She has written numerous articles and chapters, and she also speaks nationally and internationally on a regular basis. She is the past chair of the Infectious Disease Community of Practice, American Society of Transplantation, and is on the planning committee for the American Transplant Congress.

Dr. Tess McClure

Consultant Gastroenterologist and Hepatologist, Austin Health, Australia



Tess McClure has a sub-specialty interest in liver disease and transplantation, and she is currently completing a PhD at Austin Health. She studied Medicine at the University of Melbourne and completed her Gastroenterology training at St Vincent's Hospital Melbourne and Austin Health. She also completed a research degree in Medical Science at the Nossal Institute for Global Health, where she graduated with honors. For her PhD in liver transplantation, she has been awarded a Research Training Program scholarship by the University of Melbourne.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user operator manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor).

Trademarks: QIAGEN®, Sample to Insight®, QuantiFERON® (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law. PROM-21330-001 1128991 07/2022 © 2022 QIAGEN, all rights reserved.

Ordering www.qiagen.com/shop | Technical Support www.support.qiagen.com | Website www.qiagen.com